Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TROP-2-targeted antibody-drug conjugate

DRUG CLASS:

TROP-2-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	datopotamab deruxtecan-dlnk Sensitive: A1 - Approval datopotamab deruxtecan-dlnk Sensitive : A1	datopotamab deruxtecan-dlnk Sensitive: A1 - Approval datopotamab deruxtecan-dlnk Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	datopotamab deruxtecan-dlnk Sensitive: B - Late Trials datopotamab deruxtecan-dlnk Sensitive : B	datopotamab deruxtecan-dlnk Sensitive: B - Late Trials datopotamab deruxtecan-dlnk Sensitive : B
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	sacituzumab tirumotecan Sensitive: C2 – Inclusion Criteria sacituzumab tirumotecan Sensitive : C2	sacituzumab tirumotecan Sensitive: C2 – Inclusion Criteria sacituzumab tirumotecan Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	datopotamab deruxtecan-dlnk Sensitive: C2 – Inclusion Criteria datopotamab deruxtecan-dlnk Sensitive : C2	datopotamab deruxtecan-dlnk Sensitive: C2 – Inclusion Criteria datopotamab deruxtecan-dlnk Sensitive : C2
TROP2 overexpression	Non Small Cell Lung Cancer	TROP2 overexpression	Non Small Cell Lung Cancer	datopotamab deruxtecan-dlnk Sensitive: C3 – Early Trials datopotamab deruxtecan-dlnk Sensitive : C3	datopotamab deruxtecan-dlnk Sensitive: C3 – Early Trials datopotamab deruxtecan-dlnk Sensitive : C3
BRCA1 mutation	Endometrial Cancer	BRCA1 mutation	Endometrial Cancer	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3